Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

In the latest trading session, Regeneron (REGN) closed at $630.31, marking a -1.13% move from the previous day.

Regeneron (REGN) Stock Moves -1.13%: What You Should Know

NEW YORK, July 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN).

SHAREHOLDER ALERT: WeissLaw LLP Investigates Regeneron Pharmaceuticals, Inc.

Eiger BioPharmaceuticals

Coronavirus Pandemic: Regeneron And Eiger BioPharmaceuticals Positioned To Benefit From Opportunity In Treating Early Stage And At-Risk Patients

A double antibody cocktail for the treatment and prevention of COVID-19 could send this stock screaming higher, but is it a buy right now?

Is Regeneron a Good Coronavirus Stock to Buy?

AstraZeneca

BioNTech SE

Pfizer

Dozens are racing to develop a vaccine that could end the COVID-19 pandemic; so far, these companies look most likely to succeed.

4 Coronavirus Stocks to Watch This Summer

Quest Diagnostics

Labcorp Holdings Inc

Moderna

Novavax

Sanofi

COVID-19 crushed the stock market in March. The only real survivors were companies involved with testing, treatments and vaccines.

8 Coronavirus Stocks That Can Deliver Even More Upside Ahead

Vertex Pharmaceuticals

Which stock wins in a battle of two big biotechs?

Better Buy: Vertex Pharmaceuticals vs. Regeneron

BioCryst Pharmaceuticals

Biosig Technologies Inc

CytoDyn Inc.

Gilead Sciences

Immunic Inc

A cocktail of antiviral agents is more likely than a vaccine (or vaccines) to be effective in treating SARS-CoV-2 infections and preventing COVID-19.

Antivirals In The COVID-19 Space

Regeneron (REGN) closed at $615.88 in the latest trading session, marking a -0.8% move from the prior day.

Regeneron (REGN) Stock Moves -0.8%: What You Should Know

Despite a 40% rise since the March 23 lows of this year, at the current price of around $640 per share we believe Regeneron Pharmaceuticals looks attractive and it has more room for growth. Regeneron stock has rallied from $456 to $640 off the recent bottom compared to the S&P which moved 42%.

Is Regeneron Stock Attractive At $640?

Regeneron stock sports a highest-possible Composite Rating of 99. It joined the IBD list of top 50 companies this week.

Regeneron Pharmaceuticals Stock Hits New High On Coronavirus Treatment Potential

Shares of Regeneron Pharmaceuticals Inc. REGN, +1.37% were up 2.1% in trading on Thursday as SunTrust Robinson Humphrey analysts upgraded the stock to buy from hold, citing the strength of the company's drug pipeline.

Regeneron shares are up 2% after SunTrust upgrades the stock

The funding will help the biotechnology company ramp up mass production of REGN-COV2 at less financial risk before clinical trials reveal whether it works.

Regeneron Lands a $450 Million "Warp Speed" Contract for Its Prospective COVID-19 Treatment

Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.

Regeneron Initiates Studies on Experimental Coronavirus Drug

Alexion Pharma

Galapagos

Novo Nordisk

In light of Novavax Inc. (NASDAQ:NVAX) getting $1.6 billion in federal aid for its coronavirus vaccine candidate, investors might find opportunities in biotechnology stocks that have high financial strength, earnings yield and return on capital.

5 Greenblatt Magic Formula Biotech Stocks to Weather the Summer Coronavirus Storm

Major benchmarks were mixed to start the day.

The Stock Market Is Bouncing as Biotechs Climb on Coronavirus Vaccine Deals

Novavax Inc. (NASDAQ: NVAX) said on Tuesday that it inked an agreement with the U.S.

U.S. government invests in Novavax and Regeneron Pharmaceuticals under “Operation Warp Speed”

Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher on Tuesday after the company announced it has been awarded a $450 million contract to manufacture and supply REGN-COV2 Anti-Viral Antibody Cocktail.

Why Regeneron's Stock Is Trading Higher Today

Novavax Inc. (NASDAQ: NVAX) and Regeneron Pharmaceuticals Inc.

Operation Warp Speed Ramps Up With Novavax and Regeneron

The U.S. government signed a $450 million contract with Regeneron Pharmaceuticals Inc for its potential COVID-19 antibody cocktail, the drugmaker said on Tuesday.

U.S. signs $450 million contract with Regeneron for COVID-19 therapy

iShares Nasdaq Biotechnology ETF

COVID-19 has been the biggest driver of the stock market this year, whether it was the crash in March or recovery that has taken place since then.

5 Speculative COVID-19 Stocks That Could Still Surge

Regeneron Pharmaceuticals Inc said on Tuesday the U.S. government signed a $450 million contract with the drugmaker to make and supply its potential double antibody cocktail for COVID-19.

Regeneron signs $450 million contract with U.S. government for COVID-19 therapy

Shares of Regeneron Pharmaceuticals Inc. REGN, +0.77% gained 0.9% in premarket trading on Tuesday after the drugmaker said it received $450 million from the federal government to manufacture and supply its still investigational COVID-19 treatment.

Regeneron's stock gains on $450 million manufacturing deal with U.S. for experimental COVID-19 treatment

Regeneron Pharmaceuticals said on Tuesday the U.S. government has granted the drugmaker a $450 million contract to make and supply its double antibody cocktail that is being tested against Covid-19.

Regeneron signs a $450 million contract with the U.S. government for its coronavirus therapy

Regeneron Pharmaceuticals’ stock (NASDAQ: REGN) has rallied 66% year-to-date to its current level of $622, significantly outperforming the S&P500, which is down 4%, due to a rapid increase in the number Covid-19 cases resulting in heightened fears of an imminent global economic downturn.

News for Regeneron Pharmaceuticals Stock (REGN)